Labral Tear, GlenoidNCT03985839
Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip
An observational study of Labral Tear, Glenoid and Acetabular Labrum Tear, run by Smith & Nephew, Inc. at 12 sites in United States.
Trial summary
This is a prospective, multi-center, PMCF study to evaluate the safety and performance of the MICRORAPTOR REGENESORB suture anchors, MICRORAPTOR Knotless REGENESORB suture anchors, and MICRORAPTOR Knotless PEEK suture anchors implanted in 315 subjects needing reattachment of soft tissue to bone. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Labral Tear, Glenoid, Acetabular Labrum Tear, Bankart Lesions
- What is being tested?
- MICRORAPTOR™ REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor
- Type of treatment
- Medical device
- How many people
- 298 participants
- Where
- 12 sitesUnited States
- Study dates
- 1 Aug 2019to 8 Aug 2024
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Subject requires reattachment of soft tissue to bone for the following indications: * Shoulder - Capsular stabilization for Bankart repair, Anterior shoulder instability, SLAP lesion repairs, Capsular shift or capsulolabral reconstructions, Biceps tenodesis, Rotator Cuff Repairs (knotless anchors only) * Hip - Acetabular labrum repair/reconstruction
Who may be able to join
- Subject requires reattachment of soft tissue to bone for one of the following indications:
- Shoulder - Capsular stabilization for Bankart repair, anterior shoulder instability, superior labrum from anterior to posterior (SLAP) lesion repairs, capsular shift or capsulolabral reconstructions; biceps tenodesis (knotless anchors only)
- Hip - Acetabular labrum repair/reconstruction
- Subject if ≥ 18 years of age or legally authorized representative if subject is <18 years of age has consented to participate in the study by signing the IRB approved informed consent form. If <18 years of age, subject has assented to participate in the study by signing the IRB approved assent form.
- Subject is ≥12 years of age at time of surgery.
- Willing and able to make all required study visits.
- Able to follow instructions.
Who cannot join
- Known hypersensitivity to the implant material. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation.
- Pathological conditions of bone, such as cystic changes or severe osteopenia, which would compromise secure anchor fixation.
- Pathological conditions in the soft tissues to be attached that would impair secure fixation by suture.
- Comminuted bone surface, which would compromise secure anchor fixation.
- Physical conditions which would eliminate, or tend to eliminate, adequate anchor support or retard healing.
- The presence of infection.
Show all 15Show fewer
- Conditions which would limit the subject's ability or willingness to restrict activities or follow directions during the healing period.
- Currently using tobacco products (cigarette, smokeless tobacco, e-cigarettes, vaping etc.).
- Concurrent bilateral surgery.
- Prior MICRORAPTOR™ REGENESORB™, MICRORAPTOR™ Knotless REGENESORB™ or MICRORAPTOR™ Knotless PEEK implantation.
- Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1, or during the study.
- Women who are pregnant or nursing.
- History of poor compliance with medical treatment.
- Prior ipsilateral surgeries performed on the joint space.
- Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
Trial locations and contacts
12 sites in 1 country.
12 sites in 1 country
United States12 sites
Luminis Health Research Institute
Annapolis, Maryland, 21401
Memorial Medical Center
Ashland, Wisconsin, 54806
University of Colorado
Aurora, Colorado, 80045
Emory University - Brookhaven
Brookhaven, Georgia, 30329
Colorado Springs Orthopaedic Group
Colorado Springs, Colorado, 80920
Palmetto/Prisma Health - University of South Carolina Orthopaedics
Columbia, South Carolina, 29203
Ohio State University Wexner Medical Center
Columbus, Ohio, 43202
Steadman Hawkins Clinic of the Carolinas
Greenville, South Carolina, 29615
Holy Cross Orthopedic Institute
Oakland Park, Florida, 33334
Oklahoma Sports and Science Orthopedics / The Physician's Group
Oklahoma City, Oklahoma, 73114
Atlantic Orthopaedic Specialists
Virginia Beach, Virginia, 23452
Center for Advanced Orthopaedics / Nova Orthopedic & Spine Care
Woodbridge, Virginia, 22191
About this study
Official title: Prospective Multi-Center Post-Market Clinical Follow-up Study to Evaluate Safety and Performance of the MICRORAPTOR REGENESORB, Knotless REGENESORB and Knotless PEEK Suture Anchors (and MINITAPE Sutures) in Shoulder and Hip Arthroscopic Instability Repair
This is a prospective, multi-center, PMCF study to evaluate the safety and performance of the MICRORAPTOR REGENESORB suture anchors, MICRORAPTOR Knotless REGENESORB suture anchors, and MICRORAPTOR Knotless PEEK suture anchors implanted in 315 subjects needing reattachment of soft tissue to bone.
Read the detailed description
The purpose of this trial is to assess, by product, safety and performance post-market of the Microraptor Regenesorb, Microraptor Knotless Regenesorb, and Microraptor Knotless PEEK Suture Anchors.
Approximately 18 sites (approximately 3 sites for study shoulder group and 3 sites for study hip group, per product) in the United States will participate in the study. This is an open-label study with consecutive enrollment. The study will continue for 24 months from the date that the last subject received the study treatment to the date that the last subject completes the study as planned. The study duration is planned for 36 months.
- Conditions
- Labral Tear, Glenoid, Acetabular Labrum Tear, Bankart Lesions, Anterior Shoulder Instability, SLAP Lesion, Rotator Cuff Tears
- Being tested
- MICRORAPTOR™ REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor, MICRORAPTOR™ Knotless PEEK Suture Anchor
- Keywords
- Microraptor, suture anchor, knotless, Smith and Nephew
- Medical subject headings
- Rotator Cuff Injuries, Bankart Lesions
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MICRORAPTOR™ REGENESORB™ Suture AnchorDevice
Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
MICRORAPTOR™ Knotless REGENESORB™ Suture AnchorDevice
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
MICRORAPTOR™ Knotless PEEK Suture AnchorDevice
The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
| Study group | Role | What they receive |
|---|---|---|
| MICRORAPTOR™ REGENESORB™ Suture Anchor | MICRORAPTOR™ REGENESORB™ Suture Anchor Receives: Device: MICRORAPTOR™ REGENESORB™ Suture Anchor | |
| MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor | MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor Receives: Device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor | |
| MICRORAPTOR™ Knotless PEEK Suture Anchor | MICRORAPTOR™ Knotless PEEK Suture Anchor Receives: Device: MICRORAPTOR™ Knotless PEEK Suture Anchor |
What is being measured
The primary outcome is the main question the study is designed to answer.
Repair Failure Rate at 6 Months
Repair failure at 6 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 6-month follow-up.
Measured: 6 months
Secondary outcomes (11)
Repair Failure Rate at 12 Months
Repair failure at 12 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 12-month follow-up.
Measured: 12 months
Visual Analogue Scale (VAS) Pain Change From Baseline
Pain was assessed using a Visual Analogue Scale (VAS) where participants indicated their pain level by marking a point that represented their perceived pain intensity. Scores ranged from 0 to 100, with 0 representing no pain and 100 representing the worst imaginable pain (i.e., a worse outcome). A decrease in VAS Pain score indicated a reduction in pain (i.e., a better outcome) and an increase indicated worsening in pain (i.e., a worse outcome). The mean change in pain score was recorded on the VAS from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Measured: Baseline to 6 months, 12 months, and 24 months
Repair Failure Rate at 24 Months (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY)
Repair failure at 24 months was collected only for participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor. Repair failure was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 24-month follow-up.
Measured: 24 months
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on acetabular labral condition classification. The number of participants acetabular labral condition was classified as one of the following:
- Normal Intact Labrum
- Labral Tear / Degeneration
Measured: Baseline, 6 months, and 24 months
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on joint effusion classification. The number of participants joint effusion was classified as one of the following:
- None
- Mild
- Moderate
- Severe
Measured: Baseline, 6 months, and 24 months
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on the presence of bone marrow edema. The number of participants with bone marrow edema were categorized as 'Absent' or 'Present'.
Measured: Baseline, 6 months, and 24 months
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
The Rowe shoulder score for shoulder instability evaluated using a 3-item instrument completed by the investigator or qualified, delegated study staff. Its questions addressed the categories of shoulder stability (0 to 50 points), motion (0 to 20 points), and function (0 to 30 points). Scores ranged from 0 to 100 with a score of 90-100 points indicating an excellent evaluation, 75-89 points indicating a good evaluation, 51-74 points indicating a fair evaluation, and =< 50 points indicating a poor evaluation.
An increase in Rowe score indicated reduced shoulder instability (i.e., a better outcome) and a decrease indicated worsening instability (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Measured: Baseline to 6 months, 12 months, and 24 months
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Western Ontario Shoulder Instability Index (WOSI) was a participant completed instrument. Its categories included "physical symptoms", "sports, recreation, work", "pain", "lifestyle", and "emotion", with questions within each category scored from 0 to 100 using a visual analog scale. Scores were combined to produce an overall score that ranged from 0 to 2100 with a score of 0 indicating better shoulder function and 2100 indicating worse shoulder function.
A decrease in WOSI score indicated improving shoulder function (i.e., a better outcome) and an increase indicated worsening shoulder function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Measured: Baseline to 6 months, 12 months, and 24 months
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Constant-Murley Shoulder (CMS) scale assesses four aspects related to shoulder pathology: pain, activities of daily living (ADL), range of motion (ROM), and strength. The total score ranged from 0 to 100, with a higher score indicating better shoulder function.
An increase in CMS score indicated improving shoulder function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Measured: Baseline to 6 months, 12 months, and 24 months
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
The Hip Outcome Score Activities of Daily Living (HOS-ADL) subscale consisted of 17 items that addressed specific activities related to hip function. Scores ranged from 0 to 100 with 0 representing the least function and 100 representing the most function.
An increase in HOS-ADL score indicated improved hip function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Measured: Baseline to 6 months, 12 months, and 24 months
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Modified Harris Hip Score (mHHS) is a joint specific score covering domains of pain, function, functional activities, absence of deformity, and hip range of motion. Scores ranged from 0 to 100, with 0 representing worse disability and 100 representing less disability.
An increase in mHHS indicated improved hip joint function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Measured: Baseline to 6 months, 12 months, and 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jun 2019
- Study start1 Aug 2019
- Primary completion8 Aug 2024
- Study completion8 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Labral Tear, GlenoidStudies of the same condition, open and under way.
- More trials run by Smith & Nephew, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 298 participants (actual)
Sponsor and investigators
- Lead sponsor
- Smith & Nephew, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mary Ozokwere, Study chair, Smith & Nephew, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03985839
- Sponsor's protocol ID
- 2018.20.SMD.MRPTKT.PRO
- Status last verified
- Nov 2023
- First submitted
- 11 Jun 2019
- Last updated
- 13 Jul 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Multi-Center Post-Market Clinical Follow-up Study to Evaluate Safety and Performance of the MICRORAPTOR REGENESORB, Knotless REGENESORB and Knotless PEEK Suture Anchors (and MINITAPE Sutures) in Shoulder and Hip Arthroscopic Instability Repair
- ClinicalTrials.gov ID
- NCT03985839
- Acronym / sponsor ID
- 2018.20.SMD.MRPTKT.PRO
- Conditions
- Labral Tear, Glenoid, Acetabular Labrum Tear, Bankart Lesions, Anterior Shoulder Instability, SLAP Lesion, Rotator Cuff Tears
- Keywords
- Microraptor, suture anchor, knotless, Smith and Nephew
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 298 participants (actual)
- Lead sponsor
- Smith & Nephew, Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Aug 2019 (actual)
- Primary completion
- 8 Aug 2024 (actual)
- Study completion
- 8 Aug 2024 (actual)
- First posted
- 14 Jun 2019 (actual)
- Results
- Posted 13 Jul 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, multi-center, PMCF study to evaluate the safety and performance of the MICRORAPTOR REGENESORB suture anchors, MICRORAPTOR Knotless REGENESORB suture anchors, and MICRORAPTOR Knotless PEEK suture anchors implanted in 315 subjects needing reattachment of soft tissue to bone.
Detailed description
The purpose of this trial is to assess, by product, safety and performance post-market of the Microraptor Regenesorb, Microraptor Knotless Regenesorb, and Microraptor Knotless PEEK Suture Anchors.
Approximately 18 sites (approximately 3 sites for study shoulder group and 3 sites for study hip group, per product) in the United States will participate in the study. This is an open-label study with consecutive enrollment. The study will continue for 24 months from the date that the last subject received the study treatment to the date that the last subject completes the study as planned. The study duration is planned for 36 months.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| MICRORAPTOR™ REGENESORB™ Suture Anchor | – | Device: MICRORAPTOR™ REGENESORB™ Suture AnchorMICRORAPTOR™ REGENESORB™ Suture Anchor |
| MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor | – | Device: MICRORAPTOR™ Knotless REGENESORB™ Suture AnchorMICRORAPTOR™ Knotless REGENESORB™ Suture Anchor |
| MICRORAPTOR™ Knotless PEEK Suture Anchor | – | Device: MICRORAPTOR™ Knotless PEEK Suture AnchorMICRORAPTOR™ Knotless PEEK Suture Anchor |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Subject requires reattachment of soft tissue to bone for the following indications: * Shoulder - Capsular stabilization for Bankart repair, Anterior shoulder instability, SLAP lesion repairs, Capsular shift or capsulolabral reconstructions, Biceps tenodesis, Rotator Cuff Repairs (knotless anchors only) * Hip - Acetabular labrum repair/reconstruction
Key inclusion criteria (7 listed)
- Subject requires reattachment of soft tissue to bone for one of the following indications:
- Subject if ≥ 18 years of age or legally authorized representative if subject is <18 years of age has consented to participate in the study by signing the IRB approved informed consent form. If <18 years of age, subject has assented to participate in the study by signing the IRB approved assent form.
- Subject is ≥12 years of age at time of surgery.
- Willing and able to make all required study visits.
- Able to follow instructions.
Key exclusion criteria (15 listed)
- Known hypersensitivity to the implant material. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation.
- Pathological conditions of bone, such as cystic changes or severe osteopenia, which would compromise secure anchor fixation.
- Pathological conditions in the soft tissues to be attached that would impair secure fixation by suture.
- Comminuted bone surface, which would compromise secure anchor fixation.
- Physical conditions which would eliminate, or tend to eliminate, adequate anchor support or retard healing.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MICRORAPTOR™ REGENESORB™ Suture AnchorSmith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone. | Device | MICRORAPTOR™ REGENESORB™ Suture Anchor |
| MICRORAPTOR™ Knotless REGENESORB™ Suture AnchorMICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip. | Device | MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor |
| MICRORAPTOR™ Knotless PEEK Suture AnchorThe MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip. | Device | MICRORAPTOR™ Knotless PEEK Suture Anchor |
Primary outcome
Repair Failure Rate at 6 Months
Time frame: 6 months
Repair failure at 6 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 6-month follow-up.
11 secondary outcomes
Repair Failure Rate at 12 Months
Time frame: 12 months
Visual Analogue Scale (VAS) Pain Change From Baseline
Time frame: Baseline to 6 months, 12 months, and 24 months
Repair Failure Rate at 24 Months (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY)
Time frame: 24 months
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
Time frame: Baseline, 6 months, and 24 months
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Time frame: Baseline, 6 months, and 24 months
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
Time frame: Baseline, 6 months, and 24 months
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
Time frame: Baseline to 6 months, 12 months, and 24 months
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Time frame: Baseline to 6 months, 12 months, and 24 months
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Time frame: Baseline to 6 months, 12 months, and 24 months
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
Time frame: Baseline to 6 months, 12 months, and 24 months
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Time frame: Baseline to 6 months, 12 months, and 24 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Labral Tear, Glenoid
Recruiting
Hip Arthroscopy Postoperative Opioid Demands
Opioid Use, Pain
Recruiting
Blood Flow Restriction Following Hip Arthroscopy
Labral Tear, Glenoid, Femoral Acetabular Impingement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mary Ozokwere study chair
Smith & Nephew, Inc.
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Labral Tear, Glenoid and Acetabular Labrum Tear, run by Smith & Nephew, Inc. at 12 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Repair Failure Rate at 6 Months (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2026.